Alkermes Inc., J&J sales and marketing update

Johnson & Johnson's Cilag GmbH International subsidiary received exclusive rights to commercialize Alkermes' Vivitrol naltrexone to treat alcohol and opioid dependence in Russia and the Commonwealth of Independent States (CIS). Cilag's affiliate Janssen-Cilag will commercialize the drug. Alkermes will receive $5 million up front and up to $34 million in milestone payments, plus royalties. Cilag will be responsible for approval in the territories. The injectable sustained-release formulation of naltrexone in polylactide co-glycolide polymer microspheres is marketed by Cephalon Inc. (NASDAQ:CEPH, Frazer, Penn.) ...